Lebrikizumab and Stapokibart Show Efficacy in Pediatric Atopic Dermatitis Trials
Mar 16, 2026
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.